<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02821923</url>
  </required_header>
  <id_info>
    <org_study_id>Poly Vasc</org_study_id>
    <nct_id>NCT02821923</nct_id>
  </id_info>
  <brief_title>Effect of the Natural Sweeteners Erythritol and Xylitol on Vascular Function in Obese Volunteers</brief_title>
  <official_title>Effect of the Natural Sweeteners Erythritol and Xylitol on Vascular Function in Obese Volunteers: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sugar alcohols such as xylitol and erythritol are increasingly popular as sugar substitutes
      in the food industry and are also recommended to diabetic patients. Both substances are
      already in use in the food industry and are freely available. Since the 1970s, beneficial
      effects on oral health could be demonstrated as oral bacteria were influenced positively. A
      pilot study recently undertaken in the US (Flint N, 2014) has shown that diabetics profit
      from a daily intake of erythritol, as this natural sweetener enhances the elasticity of the
      blood vessels. In this trial, investigators aim to examine whether this effect can be found
      in a non-diabetic but obese cohort, and whether also xylitol improves vascular function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central arterial stiffness measured by sonography</measure>
    <time_frame>Change from baseline to 5 weeks after intake of polyol</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance measured by oral glucose tolerance test</measure>
    <time_frame>Change from baseline to 5 weeks after intake of polyol</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E967-Xylitol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24g xylitol/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E968-Erythritol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>36g erythritol/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>E967-Xylitol</intervention_name>
    <description>24g xylitol/d</description>
    <arm_group_label>E967-Xylitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>E968-Erythritol</intervention_name>
    <description>36g erythritol/d</description>
    <arm_group_label>E968-Erythritol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese volunteers (BMI &gt; 30kg/m2)

          -  Aged 18- max. 55 years

          -  Otherwise healthy.

        Exclusion Criteria:

          -  Known cardiovascular disease

          -  Diabetes mellitus

          -  Smoking and drug abuse

          -  Arterial hypertension with antihypertensive treatment

          -  Dyslipidaemia with statin therapy

          -  Known chronic hepatic disease (NASH, hepatitis).

          -  Known renal disease: kidney failure

          -  Pregnancy

          -  Chronical diseases of the gastrointestinal tract, history of gastrointestinal surgery
             with major changes to the gastrointestinal tract

          -  Substance abuse, alcohol abuse.

          -  Inability to follow procedures due to psychological disorders, dementia or
             insufficient knowledge of project language (German).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Beglinger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Claraspital Basel klinische Forschungsabteilung</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bettina WÃ¶lnerhanssen, MD</last_name>
    <email>bettina.woelnerhanssen@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina K Woelnerhanssen, MD</last_name>
      <email>bettina.woelnerhanssen@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Christoph Beglinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythritol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

